Pyridazinedione-based heterobicyclic covalent linkers and methods and applications thereof
US-2024425465-A1 · Dec 26, 2024 · US
Aminopyridazinone compounds as protein kinase inhibitors
US9951077B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9951077-B2 |
| Application number | US-201415323929-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 20, 2014 |
| Priority date | Jul 7, 2014 |
| Publication date | Apr 24, 2018 |
| Grant date | Apr 24, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure provides a compound of formula (I) and the use thereof for the therapeutic treatment of human cancers including B-cell lymphoma and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound, a tautomer, a pharmaceutically acceptable salt, a solvate, or a hydrate thereof, wherein the compound is selected from the group consisting of: 2. The compound of claim 1 , a tautomer, a pharmaceutically acceptable salt, a solvate, or a hydrate thereof, wherein the compound is 3. The compound of claim 1 , a tautomer, a pharmaceutically acceptable salt, a solvate, or a hydrate thereof, wherein the compound is
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9951077B2 cover?
- The present disclosure provides a compound of formula (I) and the use thereof for the therapeutic treatment of human cancers including B-cell lymphoma and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis.
- Who is the assignee on this patent?
- Eternity Bioscience Inc, Jiangsu Hengrui Medicine Co
- What technology area does this patent fall under?
- Primary CPC classification C07D487/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Apr 24 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).